NEWS
LifeArc invests £1.5 million in Ducentis BioTherapeutics

LifeArc’s Seed Fund has invested £1.5 million in Ducentis BioTherapeutics to develop novel drug therapies for inflammatory and autoimmune disease

Call for proposals
LifeArc seeks projects to lead to next generation sequencing diagnostics
NEWS
LifeArc monetises Keytruda® royalty interests to fund research and inves
Medicines Discovery Catapult and LifeArc launch strategic R&D partnership
LifeArc and University of Kent collaborate to develop potential pain medicines
LifeArc licenses lead stage molecules to Daiichi Sankyo
Lifearc joins Cancer Research and Ono to form Cancer Immunotherapy Alliance
Researchers
We can help to fund, develop and protect your academic research.
Working with TTOs
Our IP management skills can help protect and develop your medical research
Funding early stage research
Support for progression of medical science
Diagnostics development
Collaborative diagnostics development and validation
Drug discovery
As a charity we want to make sure your research reaches patients and minimise cost and risk for you
MRC
Support for Medical Research Council scientists
Charities
By working together we can increase our impact.
Helping charities
We help fellow charities fund, resource and develop medical research
Campaigning together
Through collaboration we give promising research every chance to succeed
Industry
We work with you to develop potential projects.
Licensing opportunities
Projects and products available for partnering and collaboration
Drug discovery pipeline
Explore the therapeutics portfolio from our Centre for Therapeutic Discovery
In vitro diagnostics
Partner with the Centre for Diagnostics Development
Antibody engineering
Our antibody engineering expertise has helped to put humanised antibody drugs on the market
Our Work
Keytruda: a new generation cancer treatment
Humanised antibody known as Keytruda (pembrolizumab)
My Interest
Academic Scientist
Pharma/Biotech
Medical Charity
MRC Scientist
Research Organisation